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Helicobacter pylori and nonsteroidal anti-inflammatory drugs (NSAIDs) are two well-known important
causative factors of gastric damage. While H. pylori increases apoptosis and the proliferation of gastric
epithelial cells and is an important factor in peptic ulcer and gastric cancer, NSAIDs induce cell apoptosis and
have antineoplastic effects. We investigated the effects of NSAIDs (a nonselective cyclooxygenase [COX]
inhibitor [indomethacin] and a selective COX-2 inhibitor [NS-398]) on the apoptosis and proliferation of
gastric epithelial cells and gastric inflammation in H. pylori-infected mice. C57BL/6 mice were sacrificed 8
weeks after H. pylori SS1 inoculation. Indomethacin (2 mg/kg) or NS-398 (10 mg/kg) was administered
subcutaneously once daily for 10 days before sacrifice. The following were assessed: gastric inflammatory
activity, gastric COX protein expression by Western blotting; gastric prostaglandin E2 levels by enzyme
immunoassay, apoptosis by terminal deoxynucleotidyltransferase-mediated dUTP nick end labeling, and cell
proliferation by Ki67 immunostaining. Compared to the controls, H. pylori infection and/or NSAID treatment
increased COX-1 and COX-2 protein expression. Gastric prostaglandin E2 levels, apoptotic index, cell prolif-
eration index, neutrophil activity, and the degree of chronic inflammation were all increased by H. pylori
infection, and these effects were significantly decreased by indomethacin treatment. However, NS-398 treat-
ment after H. pylori infection did not induce a significant reduction, although it did result in a tendency to
decrease. These results show that NSAIDs can reverse the increased apoptosis and proliferation of epithelial
cells and inflammatory activity in the stomachs of H. pylori-infected mice and that, like COX-2 activation,
COX-1 induction contributes to the change of gastric mucosal cell turnover and inflammation induced by H.
pylori infection.
Helicobacter pylori and nonsteroidal anti-inflammatory drugs
(NSAIDs) are two well-known important causative factors of
gastric injury such as gastritis and peptic ulcer. However, the
interaction between these two factors in terms of their effects
on gastric mucosa remains controversial. Some clinical studies
have reported no interaction between H. pylori and NSAIDs or
of a protective role of H. pylori in patients given NSAIDs (19,
24, 27). Other studies have shown harmful effects of H. pylori
in patients given NSAIDs (1, 4, 25). There are many reasons
for these controversies, including differences in the character-
istics of subjects, differences in methods of approach, relatively
small sample sizes, etc. Furthermore, the complicated mecha-
nisms, including cyclooxygenase 2 (COX-2) and/or COX-1 ac-
tivity, may be involved in the interaction between H. pylori and
NSAIDs (nonselective and COX-2 selective) on the gastric
mucosa. Therefore, an understanding of processes at the cel-
lular level and large studies comparing COX-2 inhibitors with
nonselective COX inhibitors will provide better information.
When one considers cell turnover and the pathogenic effects
on the gastric mucosa, it becomes apparent that the dynamic
balance between epithelial cell proliferation and apoptosis is
essential for maintaining normal mucosal integrity and that an
alteration of the balance in either direction could result in
ulcerogenesis or carcinogenesis of the stomach (38, 44). H.
pylori is associated in vivo with both increased apoptosis and
the proliferation of gastric epithelial cells; accordingly, an al-
teration in the balance of these events may lead to increased
injury or neoplastic transformation (2, 7, 34). On the other
hand, NSAIDs induce cell apoptosis and have antineoplastic
effects, and they reduce the incidence of and mortality from
colon adenocarcinoma and gastric cancer (17, 57). However, in
human clinical studies on the interaction of these two factors
during cell turnover, some controversial aspects remain unre-
solved. Zhu et al. showed that NSAIDs could abrogate the
apoptosis and proliferation enhanced by H. pylori (66). How-
ever, Leung et al. reported that the eradication of H. pylori
prior to NSAID therapy significantly reduced the level of ap-
optosis in the gastric mucosa (29).
COX expression and prostaglandin (PG) production may
have some mechanistic influence on the interaction between H.
pylori and NSAIDs in the gastric mucosa. It is well known that
COX-2 is the inducible form, involved in the inflammatory
reaction and tumorigenesis, and that COX-1 is the constitutive
form, related to physiologic cytoprotection. In H. pylori-in-
fected gastric tissue, upregulated COX-2 expression and in-
creased PGE2 production may be important for cell prolifer-
ation (13, 46). In the case of NSAID-induced gastric injury, the
* Corresponding author. Mailing address: Department of Internal
Medicine, Yonsei University College of Medicine, 134 Shinchon-dong
Seodaemun-ku, Seoul, 120-752, Korea. Phone: (822) 361-5410. Fax:
(822) 393-6884. E-mail: taeilkim@yumc.yonsei.ac.kr.
5056
most important mucosal injury factor appears to be the de-
crease in mucosal PG production by COX inhibition and ap-
optosis induction (16, 30). It has also been shown that selective
COX-2 inhibitors have antineoplastic effects, as do nonselec-
tive COX inhibitors, and that they induce less mucosal damage
than nonselective COX inhibitors (27, 49, 54). However, it has
not been determined whether there are any differences be-
tween the effects of nonselective and selective COX-2 inhibi-
tors on gastric epithelial cell kinetics in the H. pylori-infected
stomach. Therefore, in this study, we evaluated the interaction
between H. pylori and NSAIDs in terms of gastric epithelial cell
apoptosis, proliferation, and inflammation in a mouse model.
In particular, we investigated the differences between nonse-
lective and selective COX-2 inhibitors on these interactions.
MATERIALS AND METHODS
Animals and H. pylori challenge. Rat and mice models have been used to
investigate the NSAID-induced gastric damage and the effects of NSAIDs in
ulcer healing in many studies (37, 52, 61). H. pylori SS1 infection of C57BL/6
mice has been used as standardized mouse model of H. pylori infection, inducing
chronic gastritis similar to H. pylori-induced gastritis in humans (28). Therefore,
in the present study, we used the C57BL/6 mouse as the animal model.
Specific-pathogen-free, inbred C57BL/6 female mice 7 weeks of age were
purchased from Jackson Laboratory (Bar Harbor, Maine). All animals were
housed in the specific-pathogen-free barrier area of Department of Laboratory
Animal Medicine, Yonsei University College of Medicine, for the duration of the
experiments. All experiments and procedures involving the animals were re-
viewed by the Yonsei University Committee for the Care and Use of Laboratory
Animals according to university’s the guidelines and regulations for use and care
of animals.
The mice were divided into six groups A to F, and treated according to the
following schedule: A, control (n 5 7); B, H. pylori infection (n 5 7); C, H. pylori
infection followed by indomethacin treatment (n 5 7); D, H. pylori infection
followed by NS-398 treatment (n 5 5); E, indomethacin treatment (n 5 7); and
F, NS-398 treatment (n 5 5). H. pylori SS1 (vacA1 cagA1), obtained from
Daewoong Research and Development, Daewoong Pharmaceutical Co., Ltd.,
was grown on blood agar plates containing sterile sheep blood (5%, vol/vol) in
blood agar base (Becton Dickinson and Co., Cockeysville, Md.). The H. pylori
colonies were suspended in phosphate-buffered saline and administered intra-
gastrically to the mice. The animals were dosed three times in a 3-day period with
0.1 ml of bacterial suspension (approximately 109 organisms/ml). The animals
that were not inoculated with H. pylori were inoculated with identical volumes of
sterile phosphate-buffered saline alone.
Administration of NSAIDs. Indomethacin and NS-398 were purchased from
Sigma Chemical Co. (St. Louis, Mo.) and Calbiochem (La Jolla, Calif.), respec-
tively. In other experiments, NS-398 was used as a selective COX-2 inhibitor in
doses of less than 10 mg/kg (14, 37, 52); in our experiment, we found that a
13-mg/kg dose of NS-398 reduced the levels of PGE2 in mouse stomachs (n 5 5)
by approximately 35%, while a 10-mg/kg dose of NS-398 did not reduce the
gastric PGE2 level. Therefore, we decided to set the dose of selective COX-2
inhibitor at 10 mg of NS-398 per ml. Indomethacin (2 mg/kg), a nonselective
COX inhibitor, and NS-398 (10 mg/kg), a selective COX-2 inhibitor, suspended
in 1% carboxymethyl cellulose solution were administered subcutaneously in a
volume of 0.25 ml/100 g of body weight once daily for 10 days before sacrifice.
The animals that were not treated with indomethacin or NS-398 received iden-
tical volumes of vehicle (carboxymethyl cellulose) alone. Each animal was killed
8 weeks after H. pylori inoculation, and the stomach was longitudinally divided
into three pieces. One piece was fixed in 10% neutral buffered formalin for
histological examination and immunohistochemistry, and the other two pieces
were immediately stored in liquid nitrogen until assayed for the measurement of
gastric PGE2 levels and Western blotting.
Histologic gastritis and H. pylori infection. A single experienced pathologist
examined hematoxylin-eosin (H&E)- and Giemsa-stained paraffin sections of
mouse stomachs without knowledge of the experimental schedule. As semiquan-
titative estimates, the two parameters in inflammation, active inflammatory ac-
tivity (neutrophil score) and chronic inflammatory activity (mononuclear cell
score), were graded from 0 to 3, based on the updated Sydney system (9), and the
presence of spiral organisms was also examined in Giemsa-stained paraffin sec-
tions.
Western blot analysis for the measurement of gastric COX protein expression.
For analysis of gastric COX protein expression, frozen gastric tissues of mice
were homogenized and lysed in buffer containing 40 mM Tris-HCl (pH 8.0), 120
mM NaCl, 0.5% NP-40, 1 mM phenylmethylsulfonyl fluoride, and 10 mg of
leupeptin per ml. The lysate were incubated on ice for 60 min and centrifuged at
12,000 rpm for 20 min. After denaturation 20-mg aliquots of extracted proteins
were electrophoresed on sodium dodecyl sulfate–10% polyacrylamide gels and
transferred to a polyvinylidene fluoride (PVDF) membrane (Millipore, Bedford,
Mass.). The PVDF membrane was blocked with 5% nonfat milk in TBST (10
mM Tris [pH 7.4], 100 mM NaCl, 0.5% Tween 20) and then probed for 1 h with
1:1,000-diluted goat anti-COX-1 or anti-COX-2 polyclonal immunoglobulin Ig G
(IgG; Santa Cruz Biotechnology, Santa Cruz, Calif.). Bound antibodies were
detected with horseradish peroxidase-conjugated anti-goat IgG (Santa Cruz Bio-
technology), using the enhanced chemiluminescence detection system.
Enzyme immunoassay for the measurement of gastric PGE2 levels. The frozen
specimens were weighed and put in a tube containing 100% ethanol plus 10 mg
of indomethacin per ml. The samples were then minced with scissors, homoge-
nized, and centrifuged for 10 min at 12,000 rpm at 4°C. The supernatant of each
sample was used for determination of PGE2, using a Bicyclo PGE2 enzyme
immunoassay kit (Cayman Chemical Company. Ann Arbor, Mich.). as described
by the manufacturer.
Determination of apoptosis and proliferation. A single experienced patholo-
gist blinded to treatment schedule quantitated gastric epithelial cell apoptosis
and proliferation by using immunohistochemical stains. Epithelial cell apoptosis
was determined in situ from paraffin-embedded tissue sections by the terminal
deoxynucleotidyltransferase-mediated dUTP nick end-labeling (TUNEL) tech-
nique (apoTACS-Basic kit; R&D Systems, Minneapolis, Minn.) as described by
the manufacturer. All samples were processed under the same conditions with
positive and negative controls. Positive control sections were pretreated with
DNase I and negative controls were processed without terminal deoxynucleoti-
dyl-transferase. For each mouse, 50 well-oriented, representative gastric glands
were scored in a tissue section, and the results of apoptosis are expressed as
apoptotic index, defined as the number of positive cells per 50 glands.
Epithelial cell proliferation was determined by immunohistochemical staining
for Ki67. Briefly, sections were deparaffinzed, placed in citrate buffer (pH 6.0)
(10 mmol/liter), and heated in a 700-W microwave oven for 10 min. Endogenous
peroxidase activity was quenched with hydrogen peroxide, and after washing in
immunoassay buffer, the slides were incubated with a monoclonal mouse IgG
raised against Ki67 (PharMingen, San Diego, Calif.) in a humidified chamber.
Slides then were incubated with biotinylated anti-mouse IgG and streptavidin-
horseradish peroxidase (LSAB2 kit; DAKO Corporation, Carpinteria, Calif.),
developed in aminoethylcarbazole (AEC1; DAKO), and counterstained with
hematoxylin. The results of cell proliferation are expressed as proliferation index,
defined as the number of positive cells per 50 glands.
Statistics. Two-tailed statistical tests were used to evaluate the data. The
Mann-Whitney U test for nonparametric data was used to compare scores be-
tween animal groups. The correlation among apoptosis, proliferation, and in-
flammatory activity was evaluated using Spearman’s rho test for nonparametric
data. The data are presented as medians in figures and median (range) in Table
1. Significance was defined as a P value of ,0.05.
RESULTS
H. pylori infection and chronic gastritis. H. pylori infection in
the stomach was confirmed by Giemsa staining in all H. pylori-
inoculated mice (Fig. 1A), and organisms were found through-
out the glandular stomach, colonizing both the antrum and the
body, as found in a previous study (28). Increased levels of
polymorphonuclear neutrophils and mononuclear cells were
found in both the antrum and the body of the stomachs of H.
pylori-infected mice (Fig. 1B), whereas atrophy, intestinal
metaplasia, and ulceration were not observed.
PGE2 levels and COX expression. To assess the effects of H.
pylori infection and treatment with the NSAIDs indomethacin
and NS-398 on PGE2 production in gastric tissues, PGE2 levels
in the gastric tissues of mice were examined by enzyme immu-
noassay.
Gastric PGE2 levels showed a tendency to increase upon H.
pylori infection, although this was not significant, and further
VOL. 69, 2001 EFFECTS OF NSAIDs ON H. PYLORI-INFECTED STOMACHS 5057
FIG. 1. H. pylori infection, chronic gastritis, apoptosis, and proliferation in stomachs of H. pylori-infected mice. (A) Light microscopic
photograph of gastric tissue from a C57BL/6 mouse colonized with H. pylori SS1 showing the S shape of the bacteria. H. pylori infections were
confirmed by Giemsa staining in all cases of H. pylori-inoculated mice (magnification 3730). (B) Findings of chronic gastritis with many
inflammatory cells in the stomach of an H. pylori-infected mouse (H&E, 3292). (C) Increased positive apoptotic epithelial cells in the superficial
portion of the stomach of an H. pylori-infected mouse (TUNEL stain, 3292). (D) Increased numbers of positive apoptotic epithelial cells in the
proliferation compartment and superficial portion of the antral mucosa of the stomach of an H. pylori-infected mouse (TUNEL stain, 3292). (E
and F) Increased number of Ki67-positive cells in the proliferation compartment of the body (E) and antrum (F) of the stomach of an H.
pylori-infected mouse (Ki67 immunostain, 3292).
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administration of indomethacin significantly decreased this
heightened PGE2 level (P 5 0.002) (Fig. 2). However, the
effect of NS-398 treatment after H. pylori infection on PGE2
production was not significant, although it tended to decrease
to the level of the controls (Fig. 2). In the absence of H. pylori
infection, indomethacin treatment markedly decreased the
PGE2 level (P 5 0.002), but NS-398 treatment resulted in no
difference compared with the control group (Fig. 2).
We determined COX-1 and COX-2 expression levels by
Western blotting to evaluate the effect of H. pylori and/or
NSAID treatment. Levels in mouse stomachs were found to be
increased by H. pylori infection and/or NSAID treatment (Fig.
3A), and this result was confirmed by densitometric band mea-
surements (Fig. 3B).
Apoptosis of gastric epithelial cells. Because H. pylori and
gastric mucosal inflammation contribute to cell turnover, and
NSAIDs have anti-inflammatory and apoptotic effects, we in-
vestigated whether epithelial cell apoptosis is altered by H.
pylori infection and how these apoptotic effects are affected by
NSAIDs.
Apoptotic cells were detected by the TUNEL method, and
positive staining was found to be confined to the nucleus. In
the H. pylori-negative control group, TUNEL-positive cells
were few in number and usually situated at the superficial part
of the glands. However, in H. pylori-infected mice, apoptotic
cells in the superficial portion of the body and antrum were
increased in number and positive cells were often detected in
the proliferating basal zone of the antral mucosa, which is an
important site for epithelial replication and the regeneration of
mucosal glands and surface epithelium (Fig. 1C and D).
To investigate the effect of NSAIDs on apoptosis in H.
pylori-infected gastric mucosa, we measured the apoptotic in-
dex in the gastric mucosa of H. pylori-infected mouse with or
without NSAID treatment. The apoptotic index was signifi-
cantly increased upon H. pylori infection (P 5 0.003), and this
effect was significantly decreased after further treatment with
indomethacin (P 5 0.025) (Fig. 4). The apoptotic index was
also lower in H. pylori-infected mice after NS-398 treatment
than in nontreated H. pylori-infected mice, but this difference
was not statistically significant (Fig. 4). When noninfected mice
were treated with indomethacin or NS-398, no significant
change in the apoptotic indices was observed compared to the
control group (Fig. 4).
Proliferation of gastric epithelial cells. To determine
whether H. pylori infection increases proliferation in mice mu-
cosa and how NSAIDs affect the gastric epithelial cell hyper-
proliferation induced by H. pylori, epithelial cell proliferation
was quantified after challenge with H. pylori and/or NSAIDs.
Immunostaining of Ki67 was localized in the nuclei, and
FIG. 2. PGE2 levels in stomachs of H. pylori-infected mice with or
without NSAID treatment (A, control; B, H. pylori infection; C, H.
pylori infection followed by indomethacin treatment; D, H. pylori in-
fection followed by NS-398 treatment; E, indomethacin treatment; F,
NS-398 treatment). Symbols show the PGE2 levels in the gastric tissues
of mice, measured by enzyme immunoassay. Horizontal lines show the
median for each group. p, significant difference (P , 0.05) as calcu-
lated by the Mann-Whitney U test.
FIG. 3. COX expression as detected by Western blotting in stom-
achs of H. pylori-infected mice with or without NSAID treatment (A,
control; B, H. pylori infection; C, H. pylori infection followed by indo-
methacin treatment; D, H. pylori infection followed by NS-398 treat-
ment; E, indomethacin treatment; F, NS-398 treatment). (A) Western
blot analysis of COX-1 and COX-2 proteins in the gastric tissues of
mice. Extracted proteins from the gastric tissues were electrophoresed,
transferred to a PVDF membrane, and probed with anti-COX-1 and
anti-COX-2 antibodies. (B) The bands were measured densitometri-
cally, and the data were combined. Values are medians (ranges) of
optical density units in each mice group. p, significant difference (P ,
0.05) compared to the control group as calculated by the Mann-Whit-
ney U test.
FIG. 4. Apoptotic indices in stomachs of H. pylori-infected mice
with or without NSAID treatment (A, control; B, H. pylori infection; C,
H. pylori infection followed by indomethacin treatment; D, H. pylori
infection followed by NS-398 treatment; E, indomethacin treatment; F,
NS-398 treatment). Symbols show the apoptotic index (number of
positive cell per 50 glands) determined by TUNEL staining. Horizontal
lines show the median for each group. p, significant difference (P ,
0.05) as calculated by the Mann-Whitney U test.
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virtually all epithelial cells that stained positively for Ki67 were
located within the proliferating compartment, which is located
in the upper one third, the glandular neck of the body, and the
basal zone of the antrum (Fig. 1E and F). The cell proliferation
index was significantly increased after H. pylori infection (P 5
0.002), and this effect was significantly decreased by indometh-
acin (P 5 0.011) (Fig. 5). On the other hand, NS-398 treatment
after H. pylori infection led to lower cell proliferation indices
compared to the H. pylori-infected mice, but this difference was
not significant (Fig. 5). When indomethacin or NS-398 was
administered in the absence of H. pylori infection, no signifi-
cant changes in cell proliferation were observed compared to
the controls (Fig. 5).
Inflammation of gastric mucosa. To determine how
NSAIDs affect H. pylori infection-induced inflammatory activ-
ity in the stomach, we quantified neutrophils as indicators of
active inflammatory activity and mononuclear cells as indica-
tors of chronic inflammatory activity, based on the updated
Sydney system (9).
The neutrophil score was significantly increased after H.
pylori infection (P 5 0.004), and this effect was decreased
significantly by indomethacin (P 5 0.012) (Table 1). The
mononuclear cell score showed a similar pattern, increasing
after H. pylori infection (P 5 0.001) and decreasing after fur-
ther treatment with indomethacin (P 5 0.007) (Table 1). NS-
398 treatment after H. pylori infection did not induce signifi-
cant reductions in the neutrophil and mononuclear cell scores
compared to the H. pylori-infected mice (Table 1).
When indomethacin or NS-398 treatment was used in the
absence of H. pylori infection, no significant change was ob-
served in the neutrophil and mononuclear cell scores, except in
the case of the indomethacin-treated mice, which showed a
significant increase in the mononuclear cell score (P 5 0.018),
compared to the controls (Table 1).
Correlations between cell apoptosis, proliferation, and in-
flammatory activity. To determine whether increased apopto-
sis and proliferation may be related in a compensatory manner
and whether the effect of H. pylori on mucosal cell cycle events
in vivo may be associated with mucosal inflammation, we ex-
amined the relationships between apoptosis, proliferation in-
dices, and inflammatory activity. In no group of mice was a
correlation found between increased apoptosis and prolifera-
tion indices of epithelial cells or between increased apoptosis
or proliferation index and inflammatory activity.
DISCUSSION
According to epidemiological studies (40, 56), H. pylori-in-
fected subjects have a significantly higher risk of developing
peptic ulcer or gastric malignancy. It has been hypothesized
that the alteration of the balance between apoptosis and the
proliferation of gastric epithelial cells, induced by H. pylori
infection, contributes to either gastric injury such as gastritis
and peptic ulcer or carcinogenesis of the stomach (2, 7, 34).
Although H. pylori decreases epithelial cell proliferation and
induces apoptosis in vitro (5, 45, 47, 59), H. pylori infection in
vivo is associated with both increased apoptosis and prolifer-
ation (12, 41, 42). These differences between the in vivo and in
vitro results suggest that in vivo, factors including inflamma-
tory cells, extracellular matrix proteins, cytokines, and adhe-
sion molecules may also contribute to epithelial cell turnover.
The present study also confirmed that H. pylori infection in-
creases the rates of gastric epithelial cell apoptosis and prolif-
eration, as reported previously (12, 23, 34, 39, 41, 42).
Epidemiological, clinical, and animal studies have shown
that NSAIDs have an antineoplastic effect in colon cancer, and
NSAIDs also appear to reduce the incidence of and mortality
from gastric cancer (17, 57). The mechanisms responsible for
these remarkable antineoplastic effects are not understood, but
emerging data indicate that NSAIDs are likely to target several
steps along the carcinogenic pathway. These include NSAID-
induced inhibition of cell turnover, such as the induction of
apoptosis and inhibition of cell proliferation, stimulation of
immune surveillance, and antiangiogenic effects (22, 51, 55). In
the case of NSAID-induced gastric damage, it has been also
shown that NSAIDs induce the apoptosis of epithelial cells and
delay ulcer healing (52), and in combination with decreased
FIG. 5. Cell proliferation indices in stomachs of H. pylori-infected
mice with or without NSAID treatment (A, control; B, H. pylori infec-
tion; C, H. pylori infection followed by indomethacin treatment; D, H.
pylori infection followed by NS-398 treatment; E, indomethacin treat-
ment; F, NS-398 treatment). Symbols show the cell proliferation index
(number of positive cell per 50 glands) determined by Ki67 immuno-
staining. Horizontal lines show the median for each group. p, signifi-
cant difference (P , 0.05) as calculated by the Mann-Whitney U test.
TABLE 1. Neutrophil activity and degree of chronic inflammation





A 0 (0–0.5) 0 (0–0.5)
B 1.5 (0.5–2.0)c 1.0 (0.5–1.5)c
C 0.5 (0–1.0)d 0 (0–1.0)d
D 0.5 (0.5–1.5) 0.5 (0–1.5)
E 0.5 (0–1.5) 0.5 (0–1.0)c
F 0 (0–1.0) 0 (0–1.0)
a A, control; B, H. pylori infection; C, H. pylori infection followed by indo-
methacin (2 mg/kg) treatment; D, H. pylori infection followed by NS-398 (10
mg/kg) treatment; E, indomethacin treatment; F, NS-398 treatment.
b Graded from 0 to 3 by a single pathologist.
c Significantly different (P , 0.05) from controls.
d Significantly different (P , 0.05) from group B as calculated by the Mann-
Whitney U test.
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gastric PG production, this apoptosis may serve as an impor-
tant prerequisite for the gastric damage caused by NSAIDs
(34, 44, 53). In the present study, NSAID administration with-
out H. pylori infection induced no significant changes in the
proliferative and apoptotic activities of gastric epithelial cells.
In other studies, the gastric mucosal cell proliferation rates in
subjects given NSAIDs have been reported to be enhanced
(31) or to be unaffected (48), and the increased turnover of
gastric mucosa has been hypothesized to represent an adaptive
response, which is a process that gradually resolves early gas-
tric mucosal damage, despite continued exposure to NSAIDs
(15, 31). Therefore, we believe that our results regarding ef-
fects of NSAIDs on the epithelial cell turnover rate of gastric
mucosa may be explained in part by the adaptive response of
gastric mucosa.
Considering the combined effects of H. pylori and NSAIDs
on cell turnover in the stomach, interestingly, indomethacin
suppressed the apoptotic activities enhanced by H. pylori in-
fection and reversed H. pylori-mediated cell proliferation in
our study. Similar findings were reported in a clinical human
study (66). From these results, although the mechanism un-
derlying this effect is unclear and complicated, it appears that
NSAID administration can suppress uncontrolled apoptosis
and proliferation in H. pylori-infected subjects and that this
effect might be extended to subsequent processes involving
neoplastic changes. We also found that both of the inflamma-
tory activities increased by H. pylori infection were also signif-
icantly reduced by indomethacin, suggesting the anti-inflam-
matory activity of NSAIDs in the H. pylori-infected stomach.
These interesting results on cell turnover and inflammation
lead to speculation on the complicated mechanisms involving
inflammatory cells, cytokines, direct H. pylori stimuli, etc., in
the interaction between H. pylori and NSAIDs in the gastric
mucosa.
Our results also suggest that apoptosis and proliferation may
be compensatory mechanisms, counteracting excessive cell
proliferation and apoptosis, respectively (35). However, we
found no correlation between cell proliferation and apoptosis
in H. pylori-infected and/or NSAID-treated mice, in agreement
with the results of other studies (41, 66). This observation
supports the notion that the induction of apoptosis and prolif-
eration in vivo are independent events regulated by different
factors, including the direct effects of H. pylori stimuli and host
inflammatory and immune responses, involving cytokines, ni-
tric oxide, gastrin, etc. (8, 20, 36, 50).
In addition, because chronic inflammation may be a recog-
nized risk factor for epithelial carcinogenesis (63), we can
speculate about the association between cell turnover and in-
flammatory activity. However, in many other reports, inflam-
matory cytokines, oxygen free radicals, direct H. pylori stimuli,
and other factors following H. pylori infection are believed to
contribute to the increased gastric epithelial cell turnover (11,
32, 33) rather than the inflammation itself. Although the num-
ber of subjects involved was limited, our data also show that
there is no correlation between the degree of inflammation
and apoptosis or proliferation, as reported previously (33, 39,
66).
In a clinical report on the interaction between NSAIDs and
H. pylori, Hawkey et al. showed that H. pylori eradication in
long-term users of NSAIDs, with past or current peptic ulcer
or troublesome dyspepsia, led to a impaired healing of the
gastric ulcers (19), implying that under certain circumstances
some patients with H. pylori are less prone to NSAID-induced
ulceration than noninfected patients. This may be due to the
opposing effects of H. pylori and NSAIDs on PG synthesis in
the gastric mucosa (18). However, other studies have shown
that the eradication of H. pylori prior to NSAID therapy re-
duces the occurrence of peptic ulcers (4) and the level of
apoptosis in gastric mucosae (29), and that NSAID users in-
fected with H. pylori carry a greater risk of peptic ulcer than
noninfected NSAID users (1). It was also reported that H.
pylori infection may reduce the adaptation threshold and that
the eradication of H. pylori restored the ability of the gastric
mucosa to adapt to aspirin (26). However, in our results
showed no significant difference between the proliferative,
apoptotic, and inflammatory activities of NSAID-treated mice
with H. pylori infection and NSAID-treated mice without H.
pylori infection, suggesting that H. pylori infection may not
induce significant additive harmful effects in the stomachs of
subjects administered NSAIDs, as reported previously (27, 64).
The aforementioned antineoplastic and anti-inflammatory
effects of NSAIDs are commonly attributed to the inhibition of
COX-2, the inducible form of COX (62). The levels of PGs and
COX-2 gene expression are elevated in colon cancer tissue (10,
65), and the overexpression of COX-2 in epithelial cells inhib-
its apoptosis (54, 58). Although some NSAIDs were shown to
induce apoptosis by a mechanism that may be unrelated to the
ability of these drugs to inhibit PG synthesis (43), PG and
COX-2 have an important role in cell proliferation and carci-
nogenesis and are elevated in H. pylori-infected gastric mucosa
(13). In terms of COX expression as measured by Western
blotting in our mouse model, both COX-2 and COX-1 expres-
sion levels were found to be elevated in the gastric tissue of H.
pylori-infected mice compared with control mice. Wallace et al.
showed that an inflammatory response could be elicited in
COX-22/2 mice as well as wild-type mice and that this re-
sponse could be reduced in both groups by indomethacin but
not by a selective COX-2 inhibitor, which strongly suggests that
COX-1 plays a role in the inflammatory response (60). Fur-
thermore, other studies have suggested that like COX-2,
COX-1 can be induced by H. pylori (3, 21) or by stressful
stimuli such as radiation injury (6). In addition, in our present
study, along with the increased expression of both COX-1 and
COX-2 in the gastric tissue of H. pylori-infected mice, indo-
methacin treatment after H. pylori infection induced more sig-
nificant decreases in the enhanced apoptotic, proliferative, and
inflammatory activities of the H. pylori-infected stomach than
NS-398 treatment after H. pylori infection. Therefore, it is
possible that like COX-2 activation, some degree of COX-1
induction may also contribute to increased cell turnover and
the inflammatory activity induced by H. pylori infection in gas-
tric tissue. Although it is questionable that these effects trans-
late to human disease, recently Jackson et al. showed the
importance of COX-1 in H. pylori-infected humans (21).
Therefore, from the viewpoint of both gastric injury and car-
cinogenesis, it will be interesting to compare the effects of
nonselective and selective COX-2 inhibitors on gastric events
including epithelial cell kinetics, gastric injury, and its molec-
ular mechanism in H. pylori-infected humans.
In summary, NSAIDs can reverse the increased apoptosis
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and proliferation of epithelial cells and the inflammatory ac-
tivity induced by H. pylori infection in the mouse stomach, and
H. pylori does not potentiate significantly the effects on cell
turnover and inflammation induced by NSAID treatment. In
addition, like COX-2 activation, some degree of COX-1 induc-
tion might also contribute to the change in gastric mucosal cell
turnover and inflammation induced by H. pylori infection.
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